MARKET

HEPA

HEPA

Hepion Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.340
+0.080
+2.45%
After Hours: 2.900 -0.44 -13.17% 19:38 10/29 EDT
OPEN
3.260
PREV CLOSE
3.260
HIGH
3.360
LOW
3.210
VOLUME
70.85K
TURNOVER
--
52 WEEK HIGH
8.35
52 WEEK LOW
1.000
MARKET CAP
30.14M
P/E (TTM)
-1.2782
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Hepion Pharmaceuticals To Present On Therapeutic Approaches To COVID-19 And NASH At Two Virtual Conferences On October 28 And 29, 2020
EDISON, NJ / ACCESSWIRE / October 27, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company developing the drug candidate, CRV431, today announced that it will present
Benzinga · 2d ago
Hepion Pharmaceuticals to Present on Therapeutic Approaches to COVID-19 and NASH at Two Virtual Conferences on October 28 and 29, 2020
EDISON, NJ / ACCESSWIRE / October 27, 2020 / Hepion Pharmaceuticals, Inc.
ACCESSWIRE · 2d ago
Hepion announces A.I. platform for drug development
Hepion Pharmaceuticals ([[HEPA]] +1.9%) has rolled out a proprietary artificial intelligence ((AI)), machine learning platform called, AI-POWR, with an aim to identify responders a priori and reduce the need for large sample
Seekingalpha · 10/05 17:54
Hepion Pharmaceuticals Announces Proprietary A.I. Platform For Drug Development & Announces Creation Of Clinical Pharmacology Analytics Team
AI-POWR™ Driving Big Data Analytics EDISON, NJ / ACCESSWIRE / October 5, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a clinical stage biopharmaceutical company focused on
Benzinga · 10/05 11:34
Hepion Pharmaceuticals to Present at H.C. Wainwright's 4th Annual NASH Virtual Investor Conference
EDISON, NJ / ACCESSWIRE / September 29, 2020 / Hepion Pharmaceuticals, Inc.
ACCESSWIRE · 09/29 12:30
Hepion's lead drug shows antiviral activity against COVID-19
Hepion Pharmaceuticals (HEPA) jumped ~11% in premarket in reaction to positive data from a study of CRV431 conducted by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of
Seekingalpha · 09/17 12:23
Hepion Pharmaceuticals Reports Positive Activity Of CRV431 Against Coronavirus In Study Conducted By National Institute Of Allergy And Infectious Diseases
Hepion Pharmaceuticals Reports Positive Activity of CRV431 Against Coronavirus SARS-2 in Study Conducted by the National Institute of Allergy and Infectious Diseases EDISON, NJ / ACCESSWIRE / September 17, 2020
Benzinga · 09/17 12:22
Hepion Pharmaceuticals Reports Positive Activity of CRV431 Against Coronavirus SARS-2 in Study Conducted by the National Institute of Allergy and Infectious Diseases
ACCESSWIRE · 09/17 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HEPA. Analyze the recent business situations of Hepion Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HEPA stock price target is 13.00 with a high estimate of 14.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 29
Institutional Holdings: 177.78K
% Owned: 1.97%
Shares Outstanding: 9.03M
TypeInstitutionsShares
Increased
1
1.00K
New
7
-81.34K
Decreased
3
1.84K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.04%
Pharmaceuticals & Medical Research
+0.17%
Key Executives
Chairman/Director
Gary Jacob
Chief Executive Officer/Chief Scientific Officer/Director
Robert Foster
Chief Financial Officer
John Cavan
Independent Director
Thomas Adams
Independent Director
Timothy Block
Independent Director
John Brancaccio
Independent Director
Arnold Lippa
Independent Director
Peter Wijngaard
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About HEPA
Hepion Pharmaceuticals Inc., formerly ContraVir Pharmaceuticals, Inc., is a clinical stage biopharmaceutical company. The Company is focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection. Its lead oral drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. CRV431 is also being developed for viral hepatitis-induced liver disease. CRV431 targets multiple biochemical pathways involved in the progression of liver disease.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Hepion Pharmaceuticals Inc stock information, including NASDAQ:HEPA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HEPA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HEPA stock methods without spending real money on the virtual paper trading platform.